NewAmsterdam Pharma reported a net loss of $130.0 million for the nine months ended September 30, 2026, compared to $128.9 million in the prior year period. Revenue increased significantly to $25.9 million, primarily driven by $19.2 million in the third quarter, while the company maintained a strong liquidity position with $423.1 million in cash and cash equivalents.
NewAmsterdam Pharma reported third quarter 2026 financial results and highlighted the European Commission's approval of Ubeslo and Evlarco for hypercholesterolaemia. The company ended the quarter with $643.1 million in cash and expects an interim analysis of its PREVAIL cardiovascular outcomes trial in Q4 2026.
“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease. Looking ahead, we anticipate reaching the predefined event number for the planned PREVAIL interim analysis in the fourth quarter, with the outcome expected in the first quarter of 2027.”
Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma